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Diagnostic and therapeutic 
procedures in gout
ABSTRACT
Gout, a rheumatic disease caused by crystals (crystal arthropathy), is a form of inflammatory arthritis caused 
by monosodium urate depositing in the synovial fluid and as time goes by outside the joints as well (in 
other tissues and organs).Gout attacks are sudden and often result from a dietary mistake. In 2015 the 
European and American Rheumatological Associations (EULAR and ACR) published joint classification 
criteria for gout. The criteria involve gout-specific clinical symptoms, irregular results of laboratory tests 
and lesions visible in imaging tests. The “golden standard” of diagnostics still remains the presence of uric 
acid crystals in a sample of synovial fluid, the contents of the bursa and of the gouty tophus. The course of 
treatment for patients with gout depends on the stage of the disease, but it comes down to implementing 
various forms of preventing hyperuricemia by modifying the patient’s lifestyle and diet, reducing risk factors 
(such as overweight and obesity) and pharmacological treatment, both in-between and during attacks.
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Introduction
Gout, a  rheumatic disease caused by crystals 
(crystal arthropathy), is a form of inflammatory arthritis 
caused by monosodium urate depositing in the synovial 
fluid and as time goes by outside the joints as well (in 
other tissues and organs).
Gout is believed to be the most common type of 
inflammatory arthropathy in men after 40. it is 3 times 
more common in man than in women and the rate of 
incidence increases with age. it is also more common 
in developed countries, due to unhealthy lifestyle. 
The course of the disease
clinical symptoms of the disease are a result of hy-
peruricemia, which is an elevated level of uric acid. this 
happens due to a lack of balance between its supplied 
and excreted amount. Uric acid is the end product of the 
metabolic breakdown of purines, which may originate 
from food or internal metabolic processes. the overall 
amount of uric acid in the human body is estimated 
at approx. 1200mg, which translates into a blood se-
rum concentration of 5.2mg/dl (310µmol/l) in males, 
4.0mg/dl (240µmol/l) in pre-menopause females, and 
4.7mg/dl (280µmol/l) in post-menopause females. the 
daily renal excretion rate is 700–800mg. [1]
the natural course of the disease can be character-
ized by four stages:
1. asymptomatic hyperuricemia
2. Flares of joint inflammation (acute attacks of gout)
3. interparoxysmal periods
4. chronic gout (tophaceous gout) with symptoms 
of multi-joint inflammation and the formation of so-
called gouty tophi.
the most recent modification of the course of gout 
classifies it into the following stages:
1. a great risk of gout — corresponds to the hyper-
uricemia stage, both without clinical symptoms and 
without typical irregularities in imaging tests or the 
presence of uric acid crystals in microscopic tests.
2. asymptomatic hyperuricemia — a phase which 
is characterized by a  lack of symptoms with the 
presence of monosodium urate in imaging and 
microscopic tests.
3. Gout attacks
4. tophaceous gout — chronic arthritis with inflam-
mation visible in imaging tests in the form of joint 
destruction and bone erosions.
the course of treatment for patients with gout de-
pends on the stage of the disease, but it comes down 
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to implementing various forms of preventing hyper-
uricemia by modifying the patient’s lifestyle and diet, 
reducing risk factors (such as overweight and obesity) 
and pharmacological treatment, both in-between and 
during attacks. [2]
Clinical symptoms
Gout attacks are sudden and often result from a di-
etary mistake (too many purines and fructose, excessive 
portions, alcohol intake), substantive physical strain, 
fever, dehydration, effects of medication, an injury, or 
surgery. 
the symptoms of an attack have all the characteris-
tics of acute arthritis: intense pain, haphalgesia, articular 
hydrops, and anasarca. the skin around the joint is 
red, warm and tense. the first attack of gout usually 
affects the first metatarsophalangeal joint (podagra) 
and consecutive attacks may also affects this area. the 
inflammation may also affect other regions: ankle joints, 
knee joints, and rarely the joints in the upper extremi-
ties. the attacks usually affect a single joint, multi-joint 
inflammation is rarer. 
laboratory tests show an accelerated eSR, elevated 
cRP levels and neutrocytosis. the level of uric acid in 
the blood serum increases significantly, but sometimes 
it can be surprisingly normal. Proteinuria and micro-
scopic haematuria can be observed in urinalysis. an 
examination of the synovial fluid confirms inflammation 
and a microscopic evaluation in polarized light shows 
monosodium urate crystals. an ultrasound of the joints 
shows a double contour specific for gout, which is a re-
sult of deposits on the surface of the cartilage. 
Diagnosing an attack of gout based on a thorough 
history, a physical examination and basic laboratory 
test result is usually not difficult. implementing the right 
treatment significantly shortens the time-span of attacks, 
which can last several to a dozen days if untreated.
During a differential diagnosis of a gout attack in 
the form of acute inflammation of a single or multiple 
peripheral joints the following should be considered:
 — infectious, that is septic, arthritis
 — reactive arthritis 
 — peripheral joints affected by aS
 — psoriatic arthritis
 — other crystal arthropathies, such as calcium pyro-
phosphate dihydrate deposition disease (cPPD)
 — an exacerbation of osteoarthritis.
Diagnosis
in 2015 the european and american Rheumato-
logical associations (eUlaR and acR) published 
joint classification criteria for gout. [3] they apply 
to patients who had at least 1 episode of peripheral 
arthritis or bursitis (oedema, pain, or tenderness). 
the criteria involve gout-specific clinical symptoms, 
irregular results of laboratory tests and lesions 
visible in imaging tests [X-ray, ultrasound and du-
al-energy ct (dual energy computed tomography 
— Dect)].
the “golden standard” of diagnostics still remains 
the presence of uric acid crystals in a sample of syno-
vial fluid, the contents of the bursa and of the gouty 
tophus. if crystals are found, there is no need to apply 
the remaining criteria. if however, for various reasons, 
the examination of the synovial fluid is not possible, 
2015 acR-eUlaR gout classification criteria need to 
be followed. 
2015 ACR-EULAR Gout Classification 
Criteria [3, 4]
Preliminary condition: 1 episode of peripheral arthri-
tis or bursitis (oedema, pain, or tenderness).
the presence of uric acid crystals in the synovial 
fluid is sufficient to diagnose gout (if this condition is 
met, the patient can be diagnosed with gout without 
applying the criteria below)
the maximum score is 23 points. a score of ≥ 8 point 
allows to diagnose the patient with gout. the Full 
acR-eUlaR Gout classification criteria are presented 
in table 1.
Treatment of gout
the essence of gout treatment is to lower the level 
of uric acid to < 6mg/dl by modifying the patient’s 
lifestyle, implementing a proper diet and prescribing 
adequate treatment. Hyperuricemia prophylaxis, the 
difference between treating gout attacks, treating the 
disease in interparoxysmal (intercritical) periods and 
treating chronic gout should be considered. 
lifestyle and diet
 — reducing body mass in overweight and obese 
patients
 — a diet low in purines
 — increasing the frequency of physical activity
 — fighting addictions — reducing alcohol consump-
tion, especially beer consumption, and nicotine 
intake
 — primary and secondary prophylaxis of cardiovas-
cular diseases, such as ischemic heart disease 
and circulatory failure, hypertension, peripheral 
artery disease, stroke, chronic kidney disease, 
and diabetes.
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Table 1. the full acR-eUlaR Gout classification criteria table with values for each item’s score from web page: http://
goutclassificationcalculator.auckland.ac.nz/. the following website contains an algorithm of diagnostic procedures in 
accordance with the criteria and a calculator
Entry Criterion →
(Only apply criteria below to those meeting this entry criterion)
at least one episode of swelling, pain, or tenderness in a 
peripheral joint or bursa
Yes 
No
Sufficient Criterion →
(If met, can classify as gout without applying criteria below)
Presence of MSU crystals in a symptomatic joint or bursa 
(i.e., in synovial fluid) or tophus
Yes
No
Criteria 
(to be used if Sufficient criterion not met)
Score ≥ 8 required for classification as gout
categories Score
Pattern of joint/bursa involvement during symptomatic 
episode(s) ever
Joint(s) or bursa(e) other than ankle, midfoot or 1st 
MtP (or their involvement only as part of polyarticular 
presentation)
0
ankle OR midfoot (as part of monoarticular or 
oligoarticular episode without MtP1 involvement)
1
MtP1 (as part of monoarticular or oligoarticular episode) 2
Characteristics of symptomatic episode(s) ever:
1. erythema overlying affected joint (patient-reported or 
physician-observed
2. can’t bear touch or pressure to affected joint
3. Great difficulty with walking or inability to used affected joint
No characteristics 0
One characteristic 1
two characteristics 2
three characteristics 3
One typical episode 1
Recurrent typical episodes 2
Clinical evidence of tophus: draining or chalk-like 
subcutaneous nodule under transparent skin, often with 
overlying vascularity, located in typical locations: joints, ears, 
olecranon bursae, finger pads, tendons (e.g. achilles)
absent 0
Present 4
Serum urate: Measured by uricase method. ideally should 
be scored at a time when the patient was not taking urate-
lowering treatment and patient was beyond 4 weeks of 
the start of an episode (i.e., during intercritical period); if 
practicable, retest under those conditions. the highest value 
irrespective of timinig should be scored.
< 4 mg/dl -4
4 — < 6 mg/dl 0
6 — < 8 mg/dl 2
8 — < 10 mg/dl 3
≥ 10 mg/dl 4
Synovial fluid analysis of a symptomatic (ever) joint or 
bursa
Should be assessed by a trained observer
Not done
Monosodium Urate (MSU) negative
0
-2
Imaging evidence of urate depositions in symptomatic 
(ever) joint or bursa: Ultrasound evidence of double-
contour sign or dual energy computed tomography (Dect) 
demonstrating urate deposition
absent OR Not done
Present (either modality)
0
4
Imaging evidence of gout-related joint damage: 
conventional radiography of the hands and/or feet 
demonstrate at least one erosion
absent OR Not done 0
Present 4
TOTAL SCORE =
treating a gout attack
except for medication, the treatment should also in-
clude:
 — reducing the strain on the extremity with the affected 
joint
 — the extremity should be comfortable and the joint area 
should be exposed in order to reduce tenderness
 — using cold compresses
 — proper hydration (it will allow to lower the concen-
tration of uric acid).
Pharmacotherapy:
 — Colchicine — an alkaloid extracted from the au-
tumn crocus plant (colchicum autumnale), which 
reduces inflammation, although its effects are not 
yet fully known. the medication is taken during the 
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first day of the attack in an initial dose of 1.0mg, 
0.5mg after an hour and, if need be, 0.5mg after 
12 hours. in the following it is recommended to take 
0.5mg three times a day, until the symptoms resolve. 
contraindication for the use of colchicine are: renal 
or hepatic failure, pregnancy, blood disorders, heart 
function disorders, serious gastric and intestinal 
disorders. the medication shouldn’t be combined 
with macrolides, statins, or cyclosporin. the most 
common adverse effects include gastro-intestinal 
symptoms, like stomach ache, nausea, and diar-
rhea. the medication can cause liver and kidney 
dysfunction and may be myelotoxic.
 — Nonsteroidal anti-inflammatory drugs (NSAIDs) 
with the exception of aspirin (which increases the 
concentration of uric acid in blood serum) are 
alternatives to colchicine, if they are used in the 
maximum recommended therapeutic dose.
 — Glucocorticosteroids (GCs) — recommended for 
patients with colchicine and NSaiD contraindica-
tions, administered intra-articularly if possible. if this 
is difficult or impossible due to multi-joint inflamma-
tion, the medication is administered orally, initially at 
0.5mg of prednisone per kg of body mass, usually 
over the course of 5 days with a gradual reduction 
of the dosage.
 — Canakinumab — a human, monoclonal il-1b anti-
body (unavailable in Poland) intended for patients 
with frequent attacks (≥ 3 per year), who have col-
chicine, NSaiD and Gc contraindications [5].
treatment of chronic gout
in the case of recurrent attacks (> 2/year), the pres-
ence of gouty tophi, chronic arthritis, and concomitant 
diseases, such as chronic nephropathy, hypertension, 
ischemic heart disease and heart failure a  treatment 
targeted at lowering uric acid concentration should be 
considered. the aim is to achieve a uric acid concentra-
tion of < 6mg/dl and in the case of gouty tophi and/or 
chronic arthritis in the course of gout, < 5mg/dl. the 
treatment should be started no earlier than 2 weeks 
after the attack has subsided, due to the risk of anoth-
er attack.
 — Allopurinol (a xanthine oxidase inhibitor) is a first 
line treatment to reduce uric acid concentration in 
blood serum, used at an initial dose of 100mg/day, 
which is gradually increased, usually every 4 weeks, 
until the optimal dose of 300–600mg/day is reached, 
which should reduce the uric acid concentration to 
6mg/dl. 
 — Febuxostat — as an alternative to allopurinol, in 
case it’s ineffective or causes adverse effects. the 
initial dose is 80mg/day and can be increased up 
to 120mg/day [6].
in case of a gout attack, patients who regularly take 
antihyperuricemic medication, like allopurinol (allupol, 
Milurit) or febuxostat (adenuric), should not stop their 
treatment, since this would increase the risk of future 
attacks. Due to the mechanism of medications that 
decrease the level of uric acid, which may cause a gout 
attack, in the initial phase of the treatment it should 
be taken in combination with colchicine at a dose of 
0.5mg/day or with NSaiDs. 
an addition or alternative to antihyperuricemics are 
urisuric medications, like probenecid or benzbroma-
rone, which are unavailable in Poland. losartan and 
fenofibrate are known to have a weaker urisuric effect 
and should be considered, especially for patients with 
hypertension and dyslipidemia. [7, 8]
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